Specific genetic variants may determine a woman’s risk of breast cancer following treatment with selective estrogen receptor modulator drugs
In a study led by the Mayo Clinic involving patients who developed breast cancer while taking selective estrogen receptor modulator drugs, James Ingle, MD, an oncologist at Mayo Clinic, and associates at the National Surgical Adjuvant Breast and Bowel Project and the RIKEN Center for Genomic Medicine uncovered 2 genetic variations related to breast cancer risk. Researchers determined that women with unfavorable variations in these genes had a greater risk of developing breast cancer compared with women with favorable variations.
The study is published in the journal Cancer Discovery.
Source: Mayo Clinic News Release.